Sirolimus DEB in Coronary Bifurcation Lesions — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Sirolimus DEB in Coronary Bifurcation Lesions — Stella

Recruiting

Back to Coronary Bifurcation Lesions trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

Trial locations(1 site)

China

Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality

Key details

Sponsor

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Enrollment target

~280 participants

Started

March 2021

Primary completion

September 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 85 Years

Last updated May 2021

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov